CXCR7在宫颈癌中的表达及中药康艾对宫颈癌患者T淋巴细胞亚群的影响

发布时间：2018-06-03 14:10

本文选题：CXCR7 + 宫颈癌　；参考：《辽宁中医药大学》2017年硕士论文

【摘要】：目的:探究趋化因子受体7(CXCR7)沉默对He La细胞侵袭及迁移能力的影响及其在宫颈癌组织中的表达意义,为宫颈癌侵袭转移机制提供理论证据,为寻找宫颈癌生物学指标及治疗的特异性靶分子开拓新思路;探究中药康艾与胸腺五肽对宫颈癌患者T淋巴细胞亚群的影响。材料与方法:1.研究20例宫颈癌组织及5例正常宫颈组织标本均来自辽宁省肿瘤医院,宫颈癌组织标本均经病理组织学证实。利用免疫组织化学检测CXCR7在宫颈癌组织及正常宫颈组织中的表达情况。人宫颈癌细胞系He La细胞为实验室液氮常规储藏。靶向CXCR7的sh RNA质粒(CXCR7-sh RNA)或对照质粒(Ctrl-sh RNA)转染He La细胞后,通过Transwell小室法检测细胞侵袭和迁移能力变化。2.选取2014-2016于辽宁省肿瘤医院妇科住院的宫颈癌根治术后放化疗后结束后3-6个月患者30例,随机将其分为2组,每组各15例,分别给予康艾注射液和胸腺五肽进行免疫治疗,10日为一疗程,治疗1疗程后,观察其外周血T淋巴细胞亚群较治疗前变化情况。结果:1.CXCR7蛋白在宫颈癌组织中均呈阳性表达,且在正常宫颈组织中呈阴性表达。2.Transwell侵袭和迁移实验中CXCR7-sh RNA转染组He La细胞穿过基质胶和基底膜的数量显著低于阴性对照质粒转染组及未处理组。3.康艾组治疗后患者外周血T淋巴细胞亚群中CD3+、CD4+、CD8+测定值较治疗前均升高,CD4+/CD8+和NK值降低,且均具有统计学意义(P0.05)。胸腺五肽组治疗后,患者T淋巴细胞亚群CD4+、CD4+/CD8+及NK测定值较治疗前均升高,CD3+、CD8+测定值降低,且具有统计学意义(P0.05)。结论:1.宫颈癌组织中特异性高表达CXCR7,将有望成为宫颈癌早期诊断、预后判断及靶向治疗的新靶点。2.抑制He La细胞中CXCR7蛋白表达可显著抑制其侵袭迁移能力,为宫颈癌侵袭转移机制提供新的理论依据。3.中药康艾与胸腺五肽均可影响宫颈癌术后放化疗后患者外周血T淋巴细胞亚群,改善并提高患者的免疫能力,提高患者生活质量。
[Abstract]:Aim: to investigate the effect of chemokine receptor 7 (CXCR7) silencing on the invasion and migration of He-La cells and its expression in cervical carcinoma, and to provide theoretical evidence for the mechanism of invasion and metastasis of cervical cancer. In order to find out the biological indexes and specific target molecules for treatment of cervical cancer and explore the effect of Chinese medicine Kangai and thymus pentapeptide on T lymphocyte subsets in patients with cervical cancer. Materials and methods: 1. The specimens of 20 cases of cervical carcinoma and 5 cases of normal cervical tissues were all from Liaoning Provincial Cancer Hospital. The specimens of cervical carcinoma were confirmed by histopathology. Immunohistochemistry was used to detect the expression of CXCR7 in cervical carcinoma and normal cervix. Human cervical cancer cell line he La was stored in laboratory with liquid nitrogen. He-La cells were transfected with sh RNA targeting CXCR7 (CXCR7-sh RNAs) or Ctrl-sh RNAs (control plasmid Ctrl-sh RNAs). Cell invasion and migration were detected by Transwell chamber assay. Thirty patients with cervical cancer hospitalized in gynecological department of Liaoning Provincial Oncology Hospital from 2014 to 2016 were randomly divided into two groups, 15 cases in each group, 3 to 6 months after radiotherapy and chemotherapy. Kangai injection and thymus pentapeptide were given immunotherapy for 10 days. After one course of treatment, the changes of T lymphocyte subsets in peripheral blood were observed. Results: 1. The expression of CXCR7 protein was positive in cervical carcinoma. The number of He-La cells passing through matrix glue and basement membrane in CXCR7-sh RNA transfection group was significantly lower than that in negative control plasmid transfection group and untreated group. 2. The number of He-La cells passing through matrix glue and basement membrane in CXCR7-sh RNA transfection group was significantly lower than that in negative control plasmid transfection group and untreated group. In Kangai group, the levels of CD3 T lymphocyte subsets in T lymphocyte subsets were significantly higher than those before treatment, and the levels of CD 4 / CD 8 and NK were significantly lower than those before treatment (P 0.05). In the thymopeptide group, the T lymphocyte subsets (CD4, CD 4 / CD 8 and NK) were higher than those before treatment, and the CD3 / CD 8 levels were significantly lower than those before treatment, and there was a statistically significant difference between the two groups (P 0.05). Conclusion 1. The specific overexpression of CXCR7 in cervical carcinoma will be a new target for early diagnosis, prognosis judgment and targeted therapy of cervical cancer. Inhibiting the expression of CXCR7 protein in He-La cells can significantly inhibit its ability of invasion and migration, and provide a new theoretical basis for the mechanism of invasion and metastasis of cervical cancer. Both Kangai and thymus pentapeptide can affect the T lymphocyte subsets of peripheral blood of patients with cervical cancer after radiotherapy and chemotherapy, improve and improve the immune ability of patients, improve the quality of life of patients.
【学位授予单位】：辽宁中医药大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R737.33

【参考文献】